Enhanced Human Epidermal Growth Factor Receptor 2 Degradation in Breast Cancer Cells by Lysosome-Targeting Gold Nanoconstructs
Source abstract
Abstract
This paper describes how gold nanoparticle nanoconstructs can enhance anticancer effects of lysosomal targeting aptamers in breast cancer cells. Nanoconstructs consisting of anti-HER2 aptamer (human epidermal growth factor receptor 2, HApt) densely grafted on gold nanostars (AuNS) first targeted HER2 and then were internalized via HER2-mediated endocytosis. As incubation time increased, the nanoconstruct complexes were found in vesicular structures, starting from early endosomes to lysosomes as visualized by confocal fluorescence and differential interference contrast microscopy. Within the target organelle, lysosomes, HER2 was degraded by enzymes at low pH, which resulted in apoptosis. At specific time points related to the doubling time of the cancer cells, we found that accumulation of HER2-HApt-AuNS complexes in lysosomes, lysosomal activity, and lysosomal degradation of HER2 were positively correlated. Increased HER2 degradation by HApt-AuNS triggered cell death and cell cycle arrest in the G0/G1 phase inhibition of cell proliferation. This work shows how a perceived disadvantage of nanoparticle-based therapeutics-the inability of nanoconstructs to escape from vesicles and thus induce a biological response-can be overcome by both targeting lysosomes and exploiting lysosomal degradation of the biomarkers.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery · Gold and Silver Nanoparticles Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Dermatology, Northwestern University, 676 N. St. Clair Street, Chicago, Illinois 60611, United States
Funding
Robert H. Lurie Comprehensive Cancer Center, Northwestern University · National Cancer Institute · National Institute of Biomedical Imaging and Bioengineering · H Foundation Cancer Research Fund
References (55)
Show source-provided references
1. 10.1038/nrd259110.1038/nrd2591 ↗
2. 10.1021/cr300143v10.1021/cr300143v ↗
3. 10.1021/cr030698+10.1021/cr030698+ ↗
4. 10.1039/C1CS15166E10.1039/C1CS15166E ↗
5. 10.1016/j.addr.2010.07.00910.1016/j.addr.2010.07.009 ↗
6. 10.1016/j.addr.2008.03.01610.1016/j.addr.2008.03.016 ↗
7. 10.1021/nl500844m10.1021/nl500844m ↗
8. 10.1021/mp400565710.1021/mp4005657 ↗
9. 10.1021/nn300296p10.1021/nn300296p ↗
10. 10.1021/nn507095310.1021/nn5070953 ↗
11. 10.1016/j.nano.2014.10.00510.1016/j.nano.2014.10.005 ↗
12. 10.1146/annurev-med-040210-16254410.1146/annurev-med-040210-162544 ↗
13. 10.2217/nnm.14.20410.2217/nnm.14.204 ↗
14. 10.1039/c4cc01567c10.1039/c4cc01567c ↗
15. 10.3402/nano.v2i0.588310.3402/nano.v2i0.5883 ↗
16. 10.1021/bc500562s10.1021/bc500562s ↗
17. 10.1096/fj.02-0088com10.1096/fj.02-0088com ↗
18. 10.1073/pnas.15124749810.1073/pnas.151247498 ↗
19. 10.1016/S0169-409X(99)00066-610.1016/S0169-409X(99)00066-6 ↗
20. 10.1016/j.addr.2008.08.00510.1016/j.addr.2008.08.005 ↗
21. 10.1021/bm500300910.1021/bm5003009 ↗
22. 10.1039/c2ra01168a10.1039/c2ra01168a ↗
23. 10.1016/j.addr.2007.06.00810.1016/j.addr.2007.06.008 ↗
24. 10.1021/nn400704810.1021/nn4007048 ↗
25. 10.1073/pnas.130259411010.1073/pnas.1302594110 ↗
26. 10.1111/j.1365-2184.2007.00455.x10.1111/j.1365-2184.2007.00455.x ↗
27. 10.1021/nn102336310.1021/nn1023363 ↗
28. 10.1021/nn201570n10.1021/nn201570n ↗
29. 10.1021/mp500048210.1021/mp5000482 ↗
30. Roh H. · Cancer Res. · 2000 · 60 · 560
31. Münster P. N. · Cancer Res. · 2002 · 62 · 3132
32. 10.1039/c2cs15309b10.1039/c2cs15309b ↗
33. 10.1038/nnano.2008.3010.1038/nnano.2008.30 ↗
34. 10.1002/smll.20090115810.1002/smll.200901158 ↗
35. 10.1016/S0169-409X(02)00044-310.1016/S0169-409X(02)00044-3 ↗
36. 10.1038/srep0253410.1038/srep02534 ↗
37. 10.1093/annonc/12.suppl_1.S1510.1093/annonc/12.suppl_1.S15 ↗
38. 10.1093/annonc/mdi06410.1093/annonc/mdi064 ↗
39. 10.1158/1535-7163.MCT-04-028610.1158/1535-7163.MCT-04-0286 ↗
40. 10.1021/ja104317710.1021/ja1043177 ↗
41. 10.1016/j.nano.2012.05.01510.1016/j.nano.2012.05.015 ↗
42. 10.1074/jbc.M109.07333810.1074/jbc.M109.073338 ↗
43. 10.1172/JCI905410.1172/JCI9054 ↗
44. 10.1016/S1383-5718(00)00111-X10.1016/S1383-5718(00)00111-X ↗
45. Lee E. A. · Mol. Cancer Ther. · 2004 · 3 · 66110.1158/1535-7163.661.3.6 ↗
46. 10.1046/j.1365-2184.2003.00266.x10.1046/j.1365-2184.2003.00266.x ↗
47. 10.7150/thno.571610.7150/thno.5716 ↗
48. Neun B. · 2011 · 20710.1007/978-1-60327-198-1_22 ↗
49. 10.1038/nnano.2011.19110.1038/nnano.2011.191 ↗
50. 10.4161/auto.391610.4161/auto.3916 ↗
51. 10.1038/nrc173810.1038/nrc1738 ↗
52. 10.1038/nrd227210.1038/nrd2272 ↗
53. 10.1038/onc.2008.31010.1038/onc.2008.310 ↗
54. 10.1016/S0305-0491(99)00181-910.1016/S0305-0491(99)00181-9 ↗
55. Suter A. · Development · 2001 · 128 · 489910.1242/dev.128.23.4899 ↗